证券代码：000710 证券简称：贝瑞基因 公告编号：2025-049 成都市贝瑞和康基因技术股份有限公司 关于控股股东之一致行动人所持公司股份被司法拍卖的进展公告 | 股 | 是否为控 | 拍 | 本次被司 | 占其所 | 占公司 | 是否 | 东 | 股股东及 | 拍卖 | 卖 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 法拍卖数 | 持股份 | 总股本 | 为限 | 拍卖日期 | 名 | 其一致行 | 人 | 原 | 量（股） | 比例 | 比例 | 售股 | | 称 | 动人 | 因 | 2025 | 年 | 9 | | | | | | | | | 月 | 11 | 日 | 司 | 成渝 | 侯 | 10:00 | 时起 | 法 | | | | | | 是 | 400,000 | 100.00% | 0.11% | 否 | 金融 | 颖 | 至 | 2025 | 年 | 裁 | 法院 | | | 9 | 月 | 12 | 日 | 定 | 10:00 | 时止 | | | ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-048 成都市贝瑞和康基因技术股份有限公司 关于持股5%以上股东所持部分股份被司法强制执行实施结果的公告 控股股东高扬先生保证向本公司提供的信息内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"或"贝瑞基因"）于 2025年7月23日披露了《关于持股5%以上股东所持部分股份被司法强制执行的提示性公 告》（公告编号：2025-036），公司控股股东高扬先生在国信证券股份有限公司（以 下简称"国信证券"）开展的股票质押回购业务发生违约，成渝金融法院裁定强制变 现被执行人高扬先生持有的"贝瑞基因"股票不超过3,535,214股（占公司总股本比例 不超过1%），强制执行截止日期为2025年10月14日（以下简称"本次强制执行"）。 近日，公司收到了控股股东高扬先生出具的《关于持股5%以上股东所持部分股份 被强制执行实施完成的告知函》，在本次强制执行期间，高扬先生累计被强制执行 3,535,213股公司股份，占公司总 ...

控股股东高扬先生保证向本公司提供的信息内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 成都市贝瑞和康基因技术股份有限公司（以下简称"贝瑞基因"或"公司"） 于近日接到控股股东高扬先生所持有股份发生变动的通知，现将本次权益变动的 具体情况公告如下： 证券代码：000710 证券简称：贝瑞基因 公告编号：2025-047 成都市贝瑞和康基因技术股份有限公司 关于持股5%以上股东权益变动触及1%整数倍的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 本次权益变动方式 通过证券交易所的集中交易（司法强制执行） ☑ 通过证券交易所的大宗交易 □ 其他 □ 3．本次变动前后，投资者及其一致行动人拥有上市公司权益的股份情况 股份性质 本次变动前持有股份 本次变动后持有股份 股数(股) 占 总 股 本 比 例(%) 股数(股) 占总股本比 例(%) 合计持有股份 28,853,510 8.16 26,455,010 7.48 其中：无限售条件股 份 4,861,968 1.38 2,463 ...

Core Viewpoint - Berry Genomics (000710.SZ) reported a significant decline in revenue and net profit for the first half of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company achieved an operating revenue of 447 million yuan, representing a year-on-year decrease of 18.91% [1] - The net profit attributable to shareholders of the listed company was -27.24 million yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -28.59 million yuan [1] - The basic earnings per share were -0.0771 yuan [1]

Core Viewpoint - The company experienced a decline in revenue and profit during the reporting period due to industry cycles and intensified market competition, but it remains focused on core business, technological innovation, and market expansion to enhance competitiveness and improve service innovation [3][4]. Company Overview - The company did not change its controlling shareholder or actual controller during the reporting period [3]. - The company plans not to distribute cash dividends or issue bonus shares [2]. Financial Performance - In the first half of 2025, the company achieved revenue of 447,434,341.07 yuan and a net profit attributable to shareholders of -27,242,543.15 yuan, indicating a decline compared to the same period last year [3]. Business Development - The company launched the GENOisi? intelligent platform, leveraging AI in gene detection to enhance healthcare services [4][13]. - The company is advancing sequencing technology and has developed the Vega long-read sequencing platform in collaboration with PacBio, which has completed initial deliveries and testing [4][5]. - The NovaSeq 6000Dx-CN-BG sequencing instrument received medical device registration from the National Medical Products Administration (NMPA), marking a significant step towards domestic production capabilities [5]. Market Expansion - The company is expanding its overseas market presence for reproductive health and genetic disease detection products, with several products receiving EU CE certification [6][9]. - The company is conducting a multi-center prospective clinical cohort study in collaboration with over 30 institutions to optimize screening programs and promote clinical application [8]. Research and Development - The company has established partnerships with over 3,000 universities, research institutes, and hospitals, contributing to the publication of over 22,000 research papers [10]. - The company is enhancing its multi-omics product research and has optimized its Fiber-seq multi-omics solution to expand its applicability [10]. Laboratory Development - The company’s laboratories have achieved recognition from authoritative institutions, passing various quality evaluation projects and maintaining compliance with international standards [12]. AI Integration - The GENOisi? intelligent platform integrates AI to support clinical decision-making in disease prediction and diagnosis, marking a shift towards a collaborative clinical intelligence model [13][14]. - The BerryChat intelligent Q&A model has been successfully deployed in over a hundred medical institutions, enhancing the efficiency of clinical report processing [14].

Core Viewpoint - The company, Berry Genomics, has signed a maximum guarantee contract with Hangzhou United Bank for a credit facility of 40 million yuan for its wholly-owned subsidiary, Hangzhou Berry [1] Group 1 - The total amount of external guarantees provided by the company and its subsidiaries is 307 million yuan, which includes the recent guarantee [1] - This total guarantee amount represents 18.28% of the company's most recent audited net assets [1]

成都市贝瑞和康基因技术股份有限公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 法定代表人： 高扬 主管会计工作的负责人： 王冬 会计机构负责人： 高莉 | 非经营性资金占用 | 资金占用方 名称 | 占用方与上 市公司的关 联关系 | 上市公司核算的会计科目 | 2025 年期 初往来资 金余额 | 2025 年 1-6 月 往来累 计发生 金额 （不含 利息） | 2025 年 1-6 月 往来资 金的利 息(如 有) | 2025 年 1-6 月偿还累计 发生金额 | 2025 年 6 月 30 日 往来资金余额 | 占用形成 原因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 控股股东、实际控 | | | | | | | | | | | | 制人 及其附属企业 | | | | | | | | | | | | 小计 | - | - | - | | | | | | - | - | | 前控股股东、实际 | | | | | | | | | | | | 控制人 | | | | | ...

成都市贝瑞和康基因技术股份有限公司 2025 年半年度财务报告全文 成都市贝瑞和康基因技术股份有限公司 2025 年半年度财务报告 2025 年 8 月 1 成都市贝瑞和康基因技术股份有限公司 2025 年半年度财务报告全文 财务报告 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 编制单位：成都市贝瑞和康基因技术股份有限公司 2025 年 06 月 30 日 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 359,908,471.56 | 383,071,864.35 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | 10,479,041.92 | 17,032,640.72 | | 衍生金融资产 | | | | 应收票据 | 6,414,646.08 | 2,587,200.00 | | 应收账款 | 659,878,630.79 | 692,131,312.99 | | 应收款项融资 | | ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-046 成都市贝瑞和康基因技术股份有限公司 关于为全资子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保审批情况概述 成都市贝瑞和康基因技术股份有限公司（以下简称"贝瑞基因""公司"） 于 2025 年 8 月 20 日召开第十届董事会第十六次会议审议通过了《关于为全资 子公司提供担保的议案》。公司之全资子公司杭州贝瑞和康基因诊断技术有限 公司（以下简称"杭州贝瑞"）向杭州联合农村商业银行股份有限公司高沙支 行（以下简称"杭州联合银行高沙支行"）申请综合授信 4,000 万元，授信期 限 1 年。公司同意为杭州贝瑞使用上述授信所形成的债务提供连带责任保证担 保。具体内容详见公司于 2025 年 8 月 21 日在巨潮资讯网上披露的《关于为全 资子公司提供担保的公告》（公告编号：2025-042）。 5、法定代表人：高扬 6、注册资本：11,500 万元人民币 7、注册地点：浙江省杭州经济技术开发区白杨街道 6 号大街 260 号 9 幢,16 幢一层、二层 8、经营 ...

Financial Performance - The company's operating revenue for the first half of 2025 was ¥447,434,341.07, representing a decrease of 18.91% compared to ¥551,776,302.07 in the same period last year[18]. - The net loss attributable to shareholders for the first half of 2025 was ¥27,242,543.15, a decline of 394.11% from a profit of ¥9,262,843.84 in the previous year[18]. - The net cash flow from operating activities was negative at ¥31,902,432.23, a decrease of 341.76% compared to a positive cash flow of ¥13,195,640.30 in the same period last year[18]. - Basic and diluted earnings per share for the first half of 2025 were both -¥0.0771, down 394.27% from ¥0.0262 in the previous year[18]. - The company achieved revenue of ¥447,434,341.07 in the first half of 2025, with a net profit attributable to shareholders of -¥27,242,543.15[47]. - The company's revenue for the reporting period was ¥447,434,341.07, a decrease of 18.91% compared to ¥551,776,302.07 in the same period last year[60]. - The company reported a significant increase in credit impairment losses by 80.08% to -¥15,756,033.26, attributed to lower collection rates from major clients[66]. - The total comprehensive income decreased from ¥12,977,621.95 to a loss of ¥29,360,673.05, indicating a significant downturn[152]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,422,090,357.68, an increase of 1.57% from ¥2,384,723,994.06 at the end of the previous year[18]. - The net assets attributable to shareholders decreased by 2.11% to ¥1,643,967,241.41 from ¥1,679,476,362.94 at the end of the previous year[18]. - Total liabilities rose to ¥741,261,590.68, up from ¥669,562,176.39, marking an increase of around 10.70%[144]. - Owner's equity totaled ¥1,680,828,767.00, down from ¥1,715,161,817.67, showing a decrease of about 2.00%[144]. - The company reported a total current assets balance of ¥1,383,056,439.13 as of June 30, 2025, down from ¥1,439,086,278.92 at the beginning of the period, representing a decrease of approximately 3.9%[142]. Cash Flow - Operating cash flow for the first half of 2025 was negative at -¥31,902,432.23, compared to a positive 13,195,640.30 in the same period of 2024, indicating a decline in operational efficiency[157]. - Cash inflow from financing activities increased to 149,260,233.43 CNY in 2025 from 99,996,255.68 CNY in 2024, showing a growth of approximately 49%[158]. - The company reported a total cash outflow of -¥19,284,848.07 for the first half of 2025, an improvement compared to -¥49,888,963.87 in the same period of 2024[158]. Research and Development - The company is actively involved in research and development of new products and technologies to enhance its genetic testing capabilities[25]. - Research and development expenses increased from ¥39,768,904.04 to ¥52,519,317.48, an increase of approximately 32%[151]. - The company aims to increase its R&D expenditure by 17.51% in the upcoming fiscal year to drive innovation[172]. Market Strategy and Expansion - The company plans to expand its market presence by leveraging its proprietary sequencing platforms and comprehensive service offerings[25]. - The company is exploring potential mergers and acquisitions to enhance its market position and product offerings[165]. - The company plans to expand its market presence by entering two new regions in the next quarter[165]. Product Offerings - The company focuses on high-throughput sequencing technology and third-generation HiFi sequencing technology for genetic testing services and related equipment, reagents, and software sales[25]. - The company offers a comprehensive range of genetic testing services, including over 1,700 single-gene hereditary diseases and various prenatal and newborn screening tests[26]. - The company has established a comprehensive range of sequencing analysis services, utilizing leading gene sequencing platforms such as Illumina NovaSeq X Plus and PacBio Revio[30]. Risks and Challenges - The company highlighted risks and challenges in its future operations, which are detailed in the management discussion section[4]. - The company faces risks from intensified market competition and declining service prices, which could impact future performance[83]. - The company is at risk of technological and product innovation lag, which may affect market share and profitability[84]. Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares for the half-year period[92]. - The total number of ordinary shareholders at the end of the reporting period was 68,183[131]. - The largest shareholder, Chengdu Tianxing Instrument (Group) Co., Ltd., held a 12.45% stake, amounting to 44,002,000 shares, which were pledged[131].